ACP-204 + Placebo
Phase 2/3Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimer's Disease Psychosis
Conditions
Alzheimer's Disease Psychosis
Trial Timeline
Nov 14, 2023 → Feb 1, 2028
NCT ID
NCT06159673About ACP-204 + Placebo
ACP-204 + Placebo is a phase 2/3 stage product being developed by Acadia Pharmaceuticals for Alzheimer's Disease Psychosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06159673. Target conditions include Alzheimer's Disease Psychosis.
What happened to similar drugs?
20 of 20 similar drugs in Alzheimer's Disease Psychosis were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
15
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07029581 | Phase 2 | Recruiting |
| NCT06159673 | Phase 2/3 | Recruiting |
Competing Products
20 competing products in Alzheimer's Disease Psychosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY450139 + Placebo | Eli Lilly | Phase 3 | 40 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| LY450139 dihydrate + placebo | Eli Lilly | Phase 2 | 35 |
| GSK4527226 | Alector | Phase 2 | 29 |
| GSK4527226 | Alector | Phase 2 | 32 |
| AL002 | Alector | Phase 2 | 17 |
| Solanezumab + Placebo | Eli Lilly | Phase 3 | 32 |
| simufilam | Cassava Sciences | Phase 2 | 17 |
| Remternetug + Placebo | Eli Lilly | Phase 3 | 44 |
| solanezumab | Eli Lilly | Phase 2 | 35 |
| LY2886721 + Placebo | Eli Lilly | Phase 1 | 29 |
| Gantenerumab + Gantenerumab + Gantenerumab + Placebo | Chugai Pharmaceutical | Phase 1 | 29 |
| Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab. | Yuhan | Approved | 39 |
| FK962 | Astellas Pharma | Phase 2 | 27 |
| ASP0777 + Placebo | Astellas Pharma | Phase 1 | 29 |
| Elenbecestat + Placebo | Eisai | Phase 3 | 32 |
| Donepezil | Eisai | Approved | 43 |
| Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg) | Eisai | Phase 3 | 40 |
| Donepezil hydrochloride | Eisai | Phase 3 | 40 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 26 |